Claim 1: a compound having the structure of formula (1) or a pharmaceutically acceptable Salt thereof, in which X is o, s or CH2, is alquenilo C2 C2 - 6 - 6, alquinilo monocyclic heteroaryl, 5 or 6 members, CL, - 2, - N (r20) S - (alkyl C1 - 6) - S (o) - (alkyl C1 - 6) - S (o) 2 - (alkyd ILO - 6), C1 (C1 - 6 - Rent (rent) - Oh, - C1 - 6) - N (r20) - 2 - (alkyl nhso2 C1 - 6) - NHC (o) n (r20) 2 - nhoh,Or20, - C (o) - C (o) n (r20) - NHC (2 or) or R20 - NHC (or or20), or Group a and Group - OR2 of formula (1) can join to form OC - (OR) - NH -, B is a base purine or pyrimidine natural or Unnatural, or B is selected from one of the remains of a group of formulas (2)； and is N - or C - (R19)； Z is n or CH； R1 is H, or a selected Group of Formulae (3)； R2 is H,Or R1 and R2 are joined to form a selected Group of formulas (4)； R3 is alkyl haloalquilo C1 C1 - 6, - 6, - 6 alquenilo hidroxialquilo C1, C2 - 6 - 6, C2 or C3 alquinilo cycloalkyl - 7； each R4, R5, R7 and R8 is independently H C1 alkyl, - 6, - 6 hidroxialquilo haloalquilo C1, C1, 6 The or20 SR20, -, - or - N (r20) 2； each of R6, R9, R10, R11 is independently selected from h,Rent alquenilo C1 - C2 - 6, 6, 6 alquinilo C2, C3 heterocicloalquilo cycloalkyl - 7, 4 to 7 members, monocyclic heteroaryl 5 or 6 members, bicyclic heteroaryl 9 or 10 members, Halo, or20 SR20 -, -, - S - S R20 (OR), (OR) 2r20 - S (o) 2N (r20) - NHC (2 or) or20 - NHC (o) n (r20) 2, haloalquilo C1 - 6, Hydr Oxialquilo C1 - 6, - O - (haloalquilo C1 - 6), - CN, - NO2 - N (r20) 2- NH (alquileno C1 - (6) - monocyclic heteroaryl 5 or 6 Members) - NH (alquileno C1 - (6) - bicyclic heteroaryl 9 or 10 members), R20, - C (o) - C (o) or20, - C (o) n (r20) 2 and - NHC (R20), in which the group and the Group alquenilo C2 - 6 - 6 alquinilo C2 can be optionally replaced with a group Halo； R12 is H OR - (alquileno C1 - 6) - T - H OR - R21； R13 is (alquileno C1 - 6) - R21,Or R12 and R13 can join together to form a group alquileno C2 - 4 between Oxygen Atoms to th
